[1]ZHANG L, ZHAO M-H, LI ZUO, et al.China Kidney Disease Network (CK-NET) 2015 Annual Data Report[J].Kidney international supplements, 2019, 9(1):e1-e81
[2]Saran, Rajiv; Robinson, Bruce; Abbott, Kevin C.; Bragg-Gresham, Jennifer; Chen, Xiaoying; Gipson, Debbie; Gu, Haoyu; Hirth, Richard A.; Hutton, David; Jin, Yan; Kapke, Alissa; Kurtz, Vivian; Li, Yiting; McCullough, Keith; Modi, Zubin; Morgenstern, Hal; Mukhopadhyay, Purna; Pearson, Jeffrey; Pisoni, Ronald; Repeck, Kaitlyn; Schaubel, Douglas E.; Shamraj, Ruth; Steffick, Diane; Turf, Megan; Woodside, Kenneth J.; Xiang, Jie; Yin, Maggie; Zhang, Xiaosong; Shahinian, Vahakn.US Renal Data System 2019 Annual Data Report: Epidemiology of Kidney Disease in the United States[J]. American journal of kidney diseases : the official journal of the National Kidney Foundation, 2019.[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2020, 75(1 Suppl 1):A6-A7
[3]CHEUNG A K, SARNAK M J, YAN G, et al.Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study[J].Kidney international, 2004, 65(6):2380-2389
[4]STACK A G, BLOEMBERGEN W E.Prevalence and clinical correlates of coronary artery disease among new dialysis patients in the United States: a cross-sectional study[J].Journal of the American Society of Nephrology : JASN, 2001, 12(7):1516-1523
[5]FOLEY R N, PARFREY P S.Cardiac disease in chronic uremia: clinical outcome and risk factors[J].Advances in renal replacement therapy, 1997, 4(3):234-248
[6]FUNG F, SHERRARD D J, GILLEN D L, et al.Increased risk for cardiovascular mortality among malnourished end-stage renal disease patients[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2002, 40(2):307-314
[7]JUG B, PAPAZIAN J, GUPTA M, et al.Diagnostic performance of computed tomographic coronary angiography in patients with end-stage renal disease[J].Coronary artery disease, 2013, 24(2):135-141
[8]OHTAKE T, KOBAYASHI S, MORIYA H, et al.High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination[J].Journal of the American Society of Nephrology : JASN, 2005, 16(4):1141-1148
[9]KHAN N A, HEMMELGARN B R, TONELLI M, et al.Prognostic value of troponin T and I among asymptomatic patients with end-stage renal disease: a meta-analysis[J].Circulation, 2005, 112(20):3088-3096
[10]JUG B, PAPAZIAN J, GUPTA M, et al.Diagnostic performance of computed tomographic coronary angiography in patients with end-stage renal disease[J].Coronary artery disease, 2013, 24(2):135-141
[11]FERRO C J, MARK P B, KANBAY M, et al.Lipid management in patients with chronic kidney disease[J].Nature reviews. Nephrology, 2018, 14(12):727-749
[12]Wanner, Christoph; Tonelli, Marcello.KDIGO Clinical Practice Guideline for Lipid Management in CKD: summary of recommendation statements and clinical approach to the patient[J].Kidney international, 2014, 85(6):1303-1309
[13]MACH F, BAIGENT C, CATAPANO A L, et al.ESCEAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk[J].European heart journal, 2020, 41(1):111-188
[14]PATRICK B MARK1 AND PETER WINOCOUR2.Association of British Clinical Diabetologists - Renal Association (ABCD-RA) Clinical Practice Guidelines for Management of Lipids in Adults with Diabetes Mellitus and Nephropathy and/or Chronic Kidney Disease[J]. ABCD-RA, 2017.[J].ABCD-RA, 2017, 1(1):1-26
[15]HEMMELGARN B R, SOUTHERN D, CULLETON B F, et al.Survival after coronary revascularization among patients with kidney disease[J].Circulation, 2004, 110(14):1890-1895
[16]ROBERTS J K, PATEL U D.Management of coronary artery disease in end-stage renal disease[J].Seminars in dialysis, 2011, 24(5):525-532
[17]L?FMAN I, SZUMMER K, DAHLSTR?M U, et al.Associations with and prognostic impact of chronic kidney disease in heart failure with preserved,mid-range,and reduced ejection fraction[J].European journal of heart failure, 2017, 19(12):1606-1614
[18]EDWARDS N C, MOODY W E, CHUE C D, et al.Defining the natural history of uremic cardiomyopathy in chronic kidney disease: the role of cardiovascular magnetic resonance[J].JACC. Cardiovascular imaging, 2014, 7(7):703-714
[19]SARAN R, ROBINSON B, ABBOTT K C, et al.US Renal Data System 2016 Annual Data Report: Epidemiology of Kidney Disease in the United States[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2017, 69(3 Suppl 1):A7-A8
[20]WANG A Y-M, WANG M, LAM C W-K, et al.Heart failure in long-term peritoneal dialysis patients: a 4-year prospective analysis[J].Clinical journal of the American Society of Nephrology : CJASN, 2011, 6(4):805-812
[21]BANERJEE D, MA J Z, COLLINS A J, et al.Long-term survival of incident hemodialysis patients who are hospitalized for congestive heart failure,pulmonary edema,or fluid overload[J].Clinical journal of the American Society of Nephrology : CJASN, 2007, 2(6):1186-1190
[22]PANIAGUA R, VENTURA M-J, AVILA-DíAZ M, et al.NT-proBNP,fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients[J].Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2010, 25(2):551-557
[23]TUEGEL C, KATZ R, ALAM M, et al.GDF-15,Galectin 3,Soluble ST2,and Risk of Mortality and Cardiovascular Events in CKD[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2018, 72(4):519-528
[24]MCCULLOUGH P A, OLOBATOKE A, VANHECKE T E.Galectin-3: a novel blood test for the evaluation and management of patients with heart failure[J].Reviews in cardiovascular medicine, 2011, 12(4):200-210
[25]MUELLER-LENKE N, RUDEZ J, STAUB D, et al.Use of chest radiography in the emergency diagnosis of acute congestive heart failure[J].Heart (British Cardiac Society), 2006, 92(5):695-696
[26]PARK J H, JO Y-I, LEE J-H.Clinical usefulness of bioimpedance analysis for assessing volume status in patients receiving maintenance dialysis[J].The Korean journal of internal medicine, 2018, 33(4):660-669
[27]KOTT J, REICHEK N, BUTLER J, et al.Cardiac Imaging in Dialysis Patients[J].Kidney medicine, 2020, 2(5):629-638
[28]CHAWLA L S, HERZOG C A, COSTANZO M R, et al.Proposal for a functional classification system of heart failure in patients with end-stage renal disease: proceedings of the acute dialysis quality initiative (ADQI) XI workgroup[J].Journal of the American College of Cardiology, 2014, 63(13):1246-1252
[29]Upadhya, Bharathi; Rocco, Michael; Lewis, Cora E.; Oparil, Suzanne; Lovato, Laura C.; Cushman, William C.; Bates, Jeffrey T.; Bello, Natalie A.; Aurigemma, Gerard; Fine, Lawrence J.; Johnson, Karen C.; Rodriguez, Carlos J.; Raj, Dominic S.; Rastogi, Anjay; Tamariz, Leonardo; Wiggers, Alan; Kitzman, Dalane W..Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial[J].Circulation. Heart failure, 2017, 10(4):1-10
[30]RAHMAN M, FORD C E, CUTLER J A, et al.Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR[J].Clinical journal of the American Society of Nephrology : CJASN, 2012, 7(6):989-1002
[31]INRIG J K, PATEL U D, GILLESPIE B S, et al.Relationship between interdialytic weight gain and blood pressure among prevalent hemodialysis patients[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2007, 50(1):108-18
[32]AGARWAL R, ALBORZI P, SATYAN S, et al.Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized,controlled trial[J].Hypertension (Dallas, Tex.), 2009, 53(3):500-507
[33]LEON S J, TANGRI N.The Use of Renin-Angiotensin System Inhibitors in Patients WithChronic Kidney Disease[J].The Canadian journal of cardiology, 2019, 35(9):1220-1227
[34]QIAO Y, SHIN J-I, CHEN T K, et al.Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate[J].JAMA internal medicine, 2020, 180(5):718-726
[35]He, Jiang; Shlipak, Michael; Anderson, Amanda; Roy, Jason A.; Feldman, Harold I.; Kallem, Radhakrishna Reddy; Kanthety, Radhika; Kusek, John W.; Ojo, Akinlolu; Rahman, Mahboob; Ricardo, Ana C.; Soliman, Elsayed Z.; Wolf, Myles; Zhang, Xiaoming; Raj, Dominic; Hamm, Lee.Risk Factors for Heart Failure in Patients With Chronic Kidney Disease: The CRIC (Chronic Renal Insufficiency Cohort) Study[J].Journal of the American Heart Association, 2017, 6(5):1-10
[36]PERKOVIC V, JARDINE M J, NEAL B, et al.Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy[J].The New England journal of medicine, 2019, 380(24):2295-2306
[37]NEUEN B L, YOUNG T, HEERSPINK H J L, et al.SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis[J].The lancet. Diabetes & endocrinology, 2019, 7(11):845-854
[38]ZELNIKER T A, WIVIOTT S D, RAZ I, et al.SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials[J].The Lancet, 2019, 393(10166):31-39
[39]GHALI J K, WIKSTRAND J, VAN VELDHUISEN D J, et al.The influence of renal function on clinical outcome and response to beta-blockade in systolic heart failure: insights from Metoprolol CRXL Randomized Intervention Trial in Chronic HF (MERIT-HF)[J].Journal of cardiac failure, 2009, 15(4):310-318
[40]Philippe Lechat.The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial[J].The Lancet, 1999, 353(9146):9-13
[41]WEIR M A, DIXON S N, FLEET J L, et al.Blocker dialyzability and mortality in older patients receiving hemodialysis[J].Journal of the American Society of Nephrology : JASN, 2015, 26(4):987-996
[42]PITT B, PFEFFER M A, ASSMANN S F, et al.Spironolactone for heart failure with preserved ejection fraction[J].The New England journal of medicine, 2014, 370(15):1383-1392
[43]CHUA D, LO A, LO C.Spironolactone use in heart failure patients with end-stage renal disease on hemodialysis: is it safe?[J].Clinical cardiology, 2010, 33(10):604-608
[44]MATSUMOTO Y, MORI Y, KAGEYAMA S, et al.Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients[J].Journal of the American College of Cardiology, 2014, 63(6):528-536
[45]TRINH E, BARGMAN J M.Are Diuretics Underutilized in Dialysis Patients?[J].Seminars in dialysis, 2016, 29(5):338-341
[46]KIM Y-L, VAN BIESEN W.Fluid Overload in Peritoneal Dialysis Patients[J].Seminars in nephrology, 2017, 37(1):43-53
[47]MCMURRAY J J V, PACKER M, DESAI A S, et al.Angiotensin-neprilysin inhibition versus enalapril in heart failure[J].The New England journal of medicine, 2014, 371(11):993-1004
[48]SOLOMON S D, MCMURRAY J J V, ANAND I S, et al.Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction[J].The New England journal of medicine, 2019, 381(17):1609-1620
[49]HAYNES R, JUDGE P K, STAPLIN N, et al.Effects of SacubitrilValsartan Versus Irbesartan in Patients With Chronic Kidney Disease[J].Circulation, 2018, 138(15):1505-1514
[50]LEE S, OH J, KIM H, et al.Sacubitrilvalsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease[J].ESC heart failure, 2020, 7(3):1125-1129
[51]AUSTIN G STACK 1, DONALD A MOLONY, NOOR S RAHMAN, AKINSANSOYE DOSEKUN, BHAMIDIPATI MURTHY.Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States[J].Kidney international, 2003, 64(3):1071-1079
[52]MCCULLOUGH P A, CHAN C T, WEINHANDL E D, et al.Intensive Hemodialysis,Left Ventricular Hypertrophy,and Cardiovascular Disease[J].American journal of kidney diseases : the official journal of the National Kidney Foundation, 2016, 68(5S1):S5-S14
